Septic Shock Clinical Trial
— THEMISOfficial title:
A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock
Verified date | June 2014 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Interventional |
Septic shock and multi-organ failure are among the most frequent causes of death in the ICU.
Patients with septic shock require early implementation of hemodynamic therapy to keep the
duration of shock state and with it microcirculatory disturbances as short as possible. In
the septic shock guidelines by the american association SCCM the diagnosis of volume status
is based on filling pressures, like CVP. Some studies show, that the CVP depends not only on
the intravascular volume, but also on the right ventricular compliance, pulmonary vascular
resistance as well as intrathoracic pressure. The aim of the Study is to evaluate if the
duration of septic shock can be reduced through algorithm driven volume therapy orientated
to thermodilution based volume parameters (GEDI and ELWI)
Status | Completed |
Enrollment | 60 |
Est. completion date | May 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Informed consent from patient, authorized proxy, carer - In women of child bearing age, effective contraceptive use with a known failure rate of <1 % - Clinical verification of infection (= 48 hours possible), with at least one criteria from a - d required: 1. Proof of pathological microorganism in blood, sputum, urine or normally sterile body tissues 2. Identifiable focus (e.g. purulent sputum or wound secretion, perforated gut) 3. Identification of granulocytes in normally sterile tissue 4. Clinical suspicion of infection without identification of pathogens or micro-organisms (e.g. new pulmonary infiltrates on chest x-ray, treated pneumonia, purpura fulminants, necrotizing fasciitis) - Confirmation of SIRS (= 48 hours possible), with at least 2 criteria from a-d required: 1. Fever (=38 °C) or Hypothermia (= 36 °C) 2. Tachycardia (= 90/min) 3. Tachypnoea (= 20/min) or Hyperventilation (PaCO2 = 32 mmHg, = 4,4 kPa) or mechanical ventilation 4. Leukocytes (= 12,000/µl) or Leucopenia (= 4,000/µl) or = 10% immature granulocytes - Sepsis-induced HYPOTENSION despite adequate volume status (<24h): Mean arterial pressure (MAP) < 65 mmHg (< 8,7 kPa) or systolic arterial pressure (SAP) < 90 mmHg (< 12 kPa) or the need for vasopressor (Norepinephrine <0.05µg/kg/min) to support the MAP = 65 mmHg (= 8,7 kPa) or the SAP = 90 mmHg = 12 kPa), when one of these criteria has lasted for 4 hours or longer. Exclusion Criteria: - Therapy limited (DNR-Order) - Patient moribund - Pregnancy (positive pregnancy test in women of child bearing age) - Breast feeding women - Age < 18 years - Patients active treatment for congestive heart failure with Ejection fraction < 30% and/or NYHA Class IV congestive heart failure - Severe peripheral Arterial Vascular Occlusion Disease = 2b after Fontaine - Patients with Glasgow Coma Score = 8 at the time of admission and prior to the administration of medications such as sedatives - Patients with TNM stage 4 solid tumors, hematologic malignancies with high tumor burden, CNS tumors (WHO stage 4) - Patients who are likely to die within days for diseases or conditions other than catecholamine-dependent shock - Participation in another interventional clinical study within the last 30 days - Particular relationship to senior investigator (e.g. staff, relative, colleague) - Patients with severe liver dysfunction (Child C) - Patients with septic shock within the last 60 days - Patients receiving norepinephrine for longer than 48 hours |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte and Campus Virchow-Klinikum, Charité - Universitaetsmedizin Berlin | Berlin, | Berlin |
Lead Sponsor | Collaborator |
---|---|
Claudia Spies |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of septic shock | septic shock is defined as sepsis with mean arterial pressure (MAP) <65mmHg or systolic arterial pressure (SAP) <90mmHg or the need for vasopressors to support the MAP >/= 65 mmHg or the SAP >/= 90 mmHg | 6 months | Yes |
Secondary | 28 day mortality | max 28 Tage | No | |
Secondary | 90 and 180 days mortality | max 180 days | No | |
Secondary | Intensive care mortality | max 28 days | No | |
Secondary | Frequency of arterial hypoperfusion in the extremity of the thermodilution | max. 28 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A |